STOCK TITAN

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) will participate in the Stifel Targeted Oncology Days virtually on April 16-17, 2024, presenting their antibody-based therapeutics for various human diseases.
Positive
  • None.
Negative
  • None.

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel Targeted Oncology Days taking place virtually April 16 – 17, 2024.

Presentation details
Date: Tuesday, April 16
Time: 11 – 11:25 AM ET
Webcast Link: https://wsw.com/webcast/stifel

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com 

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com 
617-500-8099


FAQ

When will Compass Therapeutics (CMPX) participate in the Stifel Targeted Oncology Days?

Compass Therapeutics (CMPX) will participate in the Stifel Targeted Oncology Days virtually on April 16-17, 2024.

What is the focus of Compass Therapeutics (CMPX)?

Compass Therapeutics (CMPX) is an oncology-focused biopharmaceutical company developing antibody-based therapeutics for multiple human diseases.

Where can I find the archived corporate presentation of Compass Therapeutics (CMPX)?

The corporate presentation of Compass Therapeutics (CMPX) will be archived for 90 days on their Events page.

Compass Therapeutics, Inc.

NASDAQ:CMPX

CMPX Rankings

CMPX Latest News

CMPX Stock Data

216.01M
102.85M
13.44%
62.82%
1.18%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About CMPX

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond